Search Results - "Saldise, Elena Soria"

A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX by Rodríguez-Arbolí, Eduardo, Rodríguez-Veiga, Rebeca, Soria-Saldise, Elena, Bergua, Juan M, Caballero-Velázquez, Teresa, Arnán, Montserrat, Vives, Susana, Serrano, Josefina, Bernal, Teresa, Martínez-Sánchez, Pilar, Tormo, Mar, Rodríguez-Medina, Carlos, Herrera-Puente, Pilar, Lavilla-Rubira, Esperanza, Boluda, Blanca, Acuña-Cruz, Evelyn, Cano, Isabel, Cáceres, Sara, Ballesteros, Juan, Falantes, José, Martínez-Cuadrón, David, Pérez-Simón, José A, Montesinos, Pau

“…LAMVYX was a multicenter, single-arm, phase 2 trial designed to validate the safety and efficacy of CPX-351 in patients aged 60-75 years with newly diagnosed,…”
Get full text

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE by Martínez, Javier Alberto Rojas, Culebras, Marta García, Camacho, Rosario María Morales, Saldise, Elena Soria, Cuadrado, Isabel Montero, Antonio, Perez Simon Josè

Get full text

Graft Versus Host Disease Prophylaxis with Tacrolimus, Sirolimus and MMF in Patients Undergoing Reduced Intensity Conditioning Allogeneic Transplantation by Lopez Corral, Lucia, Blázquez Goñi, Cristina, Pérez López, Estefanía, Martín Domínguez, Francisco Manuel, Cabero Martínez, Almudena, Rodríguez Torres, Nancy, Cabrero Calvo, Monica, Espigado, Ildefonso, Martin Lopez, Ana Africa, Parody, Rocio, Baile González, Mónica, Caballero, Teresa, Cortés-Rodríguez, María, Soria Saldise, Elena, Avendaño Pita, Alejandro, Alcalde Mellado, Patricia, García Bacelar, Ana, Rodriguez Arboli, Eduardo, Lopez Parra, Miriam, Falantes, Jose Francisco, Navarro Bailon, Almudena, Vázquez López, Lourdes, Escamilla Gomez, Virginia, Sanchez-Guijo Martin, Fermin, Pérez-Simón, Jose A.

“…I ntroduction GvHD remains the leading cause of toxic morbidity and mortality (NRM) after allo-HSCT. Different prophylaxis schemes have been developed in the…”
Get full text

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens by Castaño-Bonilla, Tamara, Alonso-Dominguez, Juan M., Barragán, Eva, Rodríguez-Veiga, Rebeca, Sargas, Claudia, Gil, Cristina, Chillón, Carmen, Vidriales, María B., García, Raimundo, Martínez-López, Joaquín, Ayala, Rosa, Larrayoz, María J., Anguita, Eduardo, Cuello, Rebeca, Cantalapiedra, Alberto, Carrillo, Estrella, Soria-Saldise, Elena, Labrador, Jorge, Recio, Isabel, Algarra, Lorenzo, Rodríguez-Medina, Carlos, Bilbao-Syeiro, Cristina, López-López, Juan A., Serrano, Josefina, De Cabo, Erik, Sayas, María J., Olave, María T., Sánchez-García, Joaquín, Mateos, Mamen, Blas, Carlos, López-Lorenzo, Jose L., Lainez-Gonzalez, Daniel, Serrano, Juana, Martínez-Cuadrón, David, Sanz, Miguel A., Montesinos, Pau

“…FLT3- ITD mutations are detected in approximately 25% of newly diagnosed adult acute myeloid leukemia (AML) patients and confer an adverse prognosis. The FLT3…”
Get full text

PB1779: FLT3‐ITD MUTATION CHARACTERIZATION WITH CLASSICAL PCR METHODOLOGY VERSUS CAPTURE‐ AND AMPLICON‐BASED NGS PLATFORMS: A PETHEMA NGS‐AML PROJECT by Bilbao, Cristina, Stuckey, Ruth, Sargas, Claudia, Larráyoz, María J, Chillon, Maria Carmen, Diaz, Rosa Ayala, Carrillo, Estrella Cruz, Yébenes‐Ramírez, Manuel, Martinez‐Cuadron, David, Rodriguez‐Veiga, Rebeca, Gil, Cristina, Bernal, Teresa, Burgues, Juan Miguel Bergua, Algarra, Lorenzo, Tormo, Mar, Sanchez, Maria Pilar Martinez, Saldise, Elena Soria, Serrano, Josefina, Dominguez, Juan Manuel Alonso, Boyero, Raimundo Garcia, Amigo, Maria Luz, Herrera‐Puente, Pilar, Sayas, Maria J, Rubira, Esperanza Lavilla, Medina, Carlos Rodriguez, Sosa, Santiago Sánchez, Rodríguez‐Afonso, Jorge, Reyes‐González‐Casanova, Paula, Rodríguez‐Arbolí, Eduardo, Garcia, Joaquin Sanchez, Martinez‐Lopez, Joaquín, García‐Sanz, Ramón, Calasanz, Maria Jose, Barragan, Eva, Casares, Maria Teresa Gomez, Montesinos, Pau

Get full text